Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.48 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 0.48 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.48 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL131241 | 0.85 | P2RX1 (0.60) | P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL176304 | 0.84 | LMNA (0.57) | LMNAMAPTP2RX1TMPRSS4 | |
| SCHEMBL175583 | 0.82 | LMNA (0.56) | LMNAMAPTP2RX1TMPRSS4AVPR2 | |
| SCHEMBL27181448 | 0.80 | MAPT (0.70) | LMNAMAPTTP53ALDH1A1 | |
| SCHEMBL16709939 | 0.76 | TMPRSS4 (0.68) | LMNAMAPTTP53P2RX1TMPRSS4 | |
| SCHEMBL369199 | 0.73 | LMNA (0.51) | LMNAMAPT | |
| SCHEMBL27180681 | 0.73 | MAPT (0.72) | LMNAMAPTTP53ALDH1A1 | |
| SCHEMBL30926455 | 0.73 | MAPT (0.72) | LMNAMAPTTP53ALDH1A1 | |
| SCHEMBL3276868 | 0.73 | P2RX1 (0.53) | LMNAMAPTP2RX1TMPRSS4RXFP1 | |
| SCHEMBL130829 | 0.71 | P2RX1 (0.51) | P2RX1TMPRSS4RXFP1P2RX4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| EP-1844766-B1 | Inhibitors against the production and release of inflammatory cytokines | INST MED MOLECULAR DESIGN INC (JP) | 2012-04-18 | — | — | EP | disclosed |
| EP-1352650-B1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | INST MED MOLECULAR DESIGN INC (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | INSTITUTE OF MEDICAL MOLECULAR DESIGN INC. (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-10-09 | — | — | US | disclosed |
| US-20060014811-A1 | Medicament for treatment of cancer | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-19 | — | — | US | disclosed |
| EP-1555018-A1 | REMEDIES FOR NEURODEGENERATIVE DISEASES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1535610-A1 | THERAPEUTIC AGENT FOR CANCER | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1535609-A1 | NF-KB ACTIVATION INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080311074-A1 | Inhibitors against activation of NF-kappaB | NFKBIA, IKBKB, RELA | LMNA 953/4885MAPT 2581/4885TP53 380/4885 |
| US-20060014811-A1 | Medicament for treatment of cancer | HDAC3, HDAC1, HDAC6 | LMNA 1058/4885MAPT 2893/4885TP53 4/4885 |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | LMNA 3645/4885MAPT 1849/4885TP53 3038/4885 |
| US-20090192122-A2 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | LMNA 3899/4885MAPT 2086/4885TP53 2956/4885 |
| US-20080249071-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | LMNA 3899/4885MAPT 2086/4885TP53 2956/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | LMNA 3899/4885MAPT 2086/4885TP53 2956/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | LMNA 2842/4885MAPT 2435/4885TP53 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.